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Conventional dendritic cells (DC) are believed to rely on
membrane-bound IL-2Ra to trans-present soluble IL-2
and costimulate T cell activation and expansion. In con-
trast, Langerhans cells have been shown to use membrane-
bound IL-15Ra/IL-15 complex to activate T cells. Here we
show that, while the expansion of tumor-specific CD8+
T cells by DC matured in the presence of chronic inflam-
matory mediators (PGE2, TNFa IL-1b, IL-6) fully depends
on expression of IL-2Ra, CD8+ T cell expansion induced
by IL-12p70-producing DC matured by interferon’s and
Toll-Like receptor ligands (type-1-polarized; DC1) is both
more effective and independent of IL-2Ra expression.
While DC1-expressed IL-15Ra promotes the expansion of
tetramer-specific CD8+ T cells, their secreted levels of
IL-12p70 determines the degree of CD8+ T cell functional-
ity as evidenced by tumor antigen-specific release of IFNg
and TNFa. In accordance with the in vivo advantage of
utilizing an IL-2-independent pathway of costimulation of
tumor-specific T cells, in a retrospectively analyzed cohort
of patients with metastatic malignant melanoma treated
with cyclophosphamide and tumor-antigen transfected
DCs (NCT00978913) we observed a highly significant
inverse relation between overall survival and expression of
IL-2Ra on DC vaccine products (p = 0.009). The differen-
tial usage of IL-2Ra/IL-2 versus IL-15Ra/IL-15 pathways
by subsets of DCs helps to explain the role of different
types of inflammation in memory formation, exhaustion of
CD8+ T cell responses and progression of cancer. Further-
more, ex vivo induction of IL-15Ra/IL-15 dependent
signaling might improve adoptive T cell therapies targeting
tumors with well-defined and undefined tumor rejection
antigens.
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